Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.84 |
| ▸ | NPC1 | O15118 | 2/20 | 0.84 |
| ▸ | RAB9A | P51151 | 2/20 | 0.84 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12070966 | 1.00 | SMN1; SMN2 (0.84) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL2330005 | 1.00 | SMN1; SMN2 (0.84) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL3277860 | 0.92 | SMN1; SMN2 (0.71) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL1933206 | 0.92 | SMN1; SMN2 (0.71) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL204145 | 0.92 | SMN1; SMN2 (0.71) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL205216 | 0.91 | SMN1; SMN2 (1.00) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL14630820 | 0.91 | SMN1; SMN2 (0.69) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL10565545 | 0.91 | SMN1; SMN2 (0.69) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| Hydrochloric Acid SCHEMBL3097843 | 0.90 | SMN1; SMN2 (0.97) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL12071947 | 0.89 | SMN1; SMN2 (0.85) | SMN1; SMN2NPC1RAB9ACYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184679-A | Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-114516866-B | Preparation method of chiral 4-alkyl-pyrrole-3-formic acid compound | 南京卓康医药科技有限公司 | 2024-02-20 | — | — | CN | claimed |
| CN-114516866-A | Preparation method of chiral 4-alkyl-pyrrole-3-formic acid compound | 南京卓康医药科技有限公司 | 2022-05-20 | — | — | CN | claimed |
| EP-4656201-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | Asteroid Therapeutics (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250281424-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | ZHOU YUHANG (US) | 2025-09-11 | — | — | US | disclosed |
| US-12404279-B2 | Deubiquitinase inhibitors and methods of use thereof | MOLECURE S.A. (PL) | 2025-09-02 | — | — | US | disclosed |
| US-20250270191-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2025-08-28 | — | — | US | disclosed |
| US-20250215030-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. | 2025-06-19 | — | — | US | disclosed |
| EP-4567035-A1 | NOVEL COMPOUND AS HYPOXIA-INDUCIBLE FACTOR 1(HIF-1) INHIBITOR OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Nextgen Bioscience Co., Ltd. (KR) | 2025-06-11 | — | — | EP | disclosed |
| US-20030114443-A1 | Cyclic amine compounds as CCR5 antagonists | TOBIRA THERAPEUTICS, INC. | 2003-06-19 | — | — | US | disclosed |
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | WARNER-LAMBERT COMPANY | 2003-06-19 | — | — | US | disclosed |
| US-6562978-B1 | N-(3-(4-(4-(Aminocarbonyl)benzyl)-1-piperidinyl)propyl)-N-(3, 4-dichlorophenyl)-1-(methylsulfonyl)-4-piperidinecarboxamide or a salt thereof for treatment of AIDS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-05-13 | — | — | US | disclosed |
| WO-2002102793-A2 | QUINAZOLINEDIONES AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-12-27 | — | — | WO | disclosed |
| US-6479480-B1 | 1H-INDOLE DERIVATIVES BEARING AN OPTIONALLY SUBSTITUTED PHENYL MOIETY AT THE 2-POSITION OF THE INDOLE RING SYSTEM AND A METHYLENE-LINKED HETEROCYCLIC MOIETY AT THE 3-POSITION OF THE INDOLE RING SYSTEM; SCHIZOPHRENIA TREATMENT | MERCK SHARP & DOHME LTD. (GB) | 2002-11-12 | — | — | US | disclosed |
| EP-1220842-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2002-07-10 | — | — | EP | disclosed |
| WO-2001025200-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-12 | — | — | WO | disclosed |
| WO-2000005229-A1 | PHENYLINDOLE DERIVATIVES AS 5-HT2A RECEPTOR LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 2000-02-03 | — | — | WO | disclosed |
| US-3976660-A | Pyrrolidine derivatives | E. R. SQUIBB & SONS, INC. (US) | 1976-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | SREBF1, SREBF2, NR1H3 | SMN1; SMN2 4785/4885NPC1 79/4885RAB9A 3105/4885 |
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | ABCC1, RPS6KA1, SIGMAR1 | SMN1; SMN2 4744/4885NPC1 418/4885RAB9A 738/4885 |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | SOS1, PPM1D, PTPN1 | SMN1; SMN2 986/4885NPC1 2999/4885RAB9A 624/4885 |
| US-20250215030-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | SMN1; SMN2 3676/4885NPC1 2177/4885RAB9A 2889/4885 |
| US-20250281424-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | PF4, F12, F2 | SMN1; SMN2 4700/4885NPC1 3661/4885RAB9A 2246/4885 |
| US-20030114443-A1 | Cyclic amine compounds as CCR5 antagonists | CCR5, CCR1, CCR3 | SMN1; SMN2 3833/4885NPC1 963/4885RAB9A 2291/4885 |
| US-20250270191-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | SMN1; SMN2 4391/4885NPC1 1612/4885RAB9A 3106/4885 |
| US-12404279-B2 | Deubiquitinase inhibitors and methods of use thereof | USP7, USP28, USP1 | SMN1; SMN2 2139/4885NPC1 1121/4885RAB9A 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.